ImmuPharma (LON:IMM) Trading Down 10% - Here's What Happened

Key Points

• ImmuPharma's share price fell by 10% on Monday, closing at GBX 11.25 ($0.15) after reaching a low of GBX 10.51 ($0.14).
• The company has a market cap of £56.23 million and a significant PE ratio of -1,264.38, indicating financial challenges.
• ImmuPharma's lead program, P140 (Lupuzor™), aims to treat Lupus and shows potential therapeutic activity for other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price dropped 10% during mid-day trading on Monday . The company traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares were traded during trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Up 9.5%

The stock has a 50 day simple moving average of GBX 4.46 and a two-hundred day simple moving average of GBX 3.33. The stock has a market capitalization of £60.47 million, a P/E ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.